Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.

× No keyword cloud information.

43 in total

Review 1. Molecular monitoring of BCR-ABL transcripts in patients with chronic myelogenous leukemia: is high sensitivity of clinical value?

Authors: Maxim Norkin; Charles A Schiffer
Journal: Curr Hematol Malig Rep Date: 2010-04 Impact factor: 3.952

2. Molecular characterization of canine BCR-ABL-positive chronic myelomonocytic leukemia before and after chemotherapy.

Authors: Sarah Culver; Daisuke Ito; Luke Borst; Jerold S Bell; Jaime F Modiano; Matthew Breen
Journal: Vet Clin Pathol Date: 2013-06-25 Impact factor: 1.180

Review 3. Laboratory Monitoring of Chronic Myeloid Leukemia in Patients on Tyrosine Kinase Inhibitors.

Authors: Richa Chauhan; Sudha Sazawal; H P Pati
Journal: Indian J Hematol Blood Transfus Date: 2018-03-13 Impact factor: 0.900

Review 4. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.

Authors: Hagop Kantarjian; Susan O'Brien; Jorge Cortes; William Wierda; Stefan Faderl; Guillermo Garcia-Manero; Jean-Pierre Issa; Elihu Estey; Michael Keating; Emil J Freireich
Journal: Cancer Date: 2008-10-01 Impact factor: 6.860

5. Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.

Authors: Hagop Kantarjian; Jorge Cortes
Journal: J Clin Oncol Date: 2011-03-21 Impact factor: 44.544

6. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).

Authors: Timothy P Hughes; Andreas Hochhaus; Susan Branford; Martin C Müller; Jaspal S Kaeda; Letizia Foroni; Brian J Druker; François Guilhot; Richard A Larson; Stephen G O'Brien; Marc S Rudoltz; Manisha Mone; Elisabeth Wehrle; Vijay Modur; John M Goldman; Jerald P Radich
Journal: Blood Date: 2010-08-02 Impact factor: 22.113

Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.

Review 1. Molecular monitoring of BCR-ABL transcripts in patients with chronic myelogenous leukemia: is high sensitivity of clinical value?

2. Molecular characterization of canine BCR-ABL-positive chronic myelomonocytic leukemia before and after chemotherapy.

Review 3. Laboratory Monitoring of Chronic Myeloid Leukemia in Patients on Tyrosine Kinase Inhibitors.

Review 4. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.

5. Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.

6. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).

7. How I treat childhood CML.

Review 8. Current developments in molecular monitoring in chronic myeloid leukemia.

9. Targeted treatment of chronic myeloid leukemia: role of imatinib.

10. Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia.